Zoegenix Climbs on Clinical Trial Results

On September 29, Zogenix (ZGNX) reported positive results from its phase 3 clinical trial for the drug ZX008. The drug treats a rare form of epilepsy known as Dravet Syndrome.

 

Sonal caught the news at 7:00 am and sent out a level 2 alert.

The stock price immediately surged but then faded after the first hour of trading. The price started trending up again later in the morning. Sonal subscribers who received the alert had the opportunity to trade the morning surge and fade along with the upward trend throughout the day. Zogenix shares closed up over 11% from the open.

The stock price continued to rise in the next few trading days after the event. Subscribers who received the alert and traded at the opening price of $31.45 were able to earn almost a 20% return over three days.

Visit the Knowledge Center for more information about trading clinical trials.

 

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!